Experienced in Turcot Syndrome

Henk M. Verheul

Erasmus MC
Rotterdam, ZH, NL 
Experienced in Turcot Syndrome
Erasmus MC
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Henk Verheul practices in Rotterdam, Netherlands. Verheul is rated as an Experienced expert by MediFind in the treatment of Turcot Syndrome. Their top areas of expertise are Colorectal Cancer, Astrocytoma, Glioblastoma, Adenocarcinoid Tumor, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 263 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Turcot Syndrome.

Locations

Erasmus MC
Rotterdam, ZH, Netherlands
Other Locations
Radboudumc
Nijmegen, GE 6525GA, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drug: Zenocutuzumab
Study Phase: Phase 2
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2
Perioperative Systemic Therapy and Cytoreductive Surgery with HIPEC Versus Upfront Cytoreductive Surgery with HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study
Perioperative Systemic Therapy and Cytoreductive Surgery with HIPEC Versus Upfront Cytoreductive Surgery with HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2024
Intervention Type: Combination product, Procedure, Other
Study Phase: Phase 2/Phase 3
Watchful Waiting in Patients With Good and Intermediate Risk Metastatic Renal Cell Carcinoma; an Imaging Guided Observational Approach. Part of: Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging. IMPACT Study: Imaging Patients for Cancer Drug Selection
Watchful Waiting in Patients With Good and Intermediate Risk Metastatic Renal Cell Carcinoma; an Imaging Guided Observational Approach. Part of: Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging. IMPACT Study: Imaging Patients for Cancer Drug Selection
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Procedure
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
Enrollment Status: Terminated
Publish Date: November 20, 2020
View 4 Less Clinical Trials

263 Total Publications

Critical Evaluation of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Critical Evaluation of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Journal: JCO oncology practice
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Verheul's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile